Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$358.5M
TTM
Current Assets
$28.41M
Q2 2024
Current Liabilities
$12.65M
Q2 2024
Current Ratio
224.62%
Q2 2024
Total Assets
$34.57M
Q2 2024
Total Liabilities
$13.77M
Q2 2024
Book Value
$20.81M
Q2 2024
Cash
$25.93M
Q2 2024
P/E
-0.03208
Nov 29, 2024 EST
Free Cash Flow
-$59.23M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021
Revenue $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021
Revenue $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021
Selling, General & Admin $19.95M $1.805M $185.6K
YoY Change 1005.31% 872.49% -98.32%
% of Gross Profit
Research & Development $34.19M $35.46M $35.57M
YoY Change -3.56% -0.31% 13.13%
% of Gross Profit
Depreciation & Amortization $669.0K
YoY Change
% of Gross Profit
Operating Expenses $34.19M $1.805M $185.6K
YoY Change 1794.72% 872.49% -99.41%
Operating Profit
YoY Change

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021
Interest Expense $4.212M $1.222M $8.190K
YoY Change 244.69% 14820.02% -95.45%
% of Operating Profit
Other Income/Expense, Net $464.0K
YoY Change

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021
Pretax Income -$172.6M -$582.7K -$177.4K
YoY Change 29519.19% 228.49% -99.76%
Income Tax $10.00K $94.78K
% Of Pretax Income
Net Earnings -$172.6M -$677.5K -$177.4K
YoY Change 25376.91% 281.92% -99.76%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.93 -$0.05 -$0.03

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021
Cash & Short-Term Investments $37.82M $107.3M $599.0K
YoY Change -64.77% 17820.69%
Cash & Equivalents $32.06M
Short-Term Investments $5.761M $107.3M
Other Short-Term Assets $2.108M $0.00 $154.0K
YoY Change -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $39.93M $107.3M $752.9K
YoY Change -62.8% 14155.82%
Property, Plant & Equipment $586.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $105.1M
YoY Change -100.0%
Other Assets $119.0K
YoY Change
Total Long-Term Assets $15.46M $0.00 $105.1M
YoY Change -100.0%
Total Assets $55.39M $107.3M $105.8M
YoY Change
Accounts Payable $2.141M $34.20K
YoY Change 6160.32%
Accrued Expenses $9.162M $94.78K
YoY Change 9566.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.394M
YoY Change
Total Short-Term Liabilities $13.56M $5.858M $34.20K
YoY Change 131.4% 17029.56%
Long-Term Debt $267.0K $0.00 $0.00
YoY Change
Other Long-Term Liabilities $330.0K $0.00 $3.623M
YoY Change -100.0%
Total Long-Term Liabilities $597.0K $0.00 $3.623M
YoY Change -100.0%
Total Liabilities $14.15M $5.858M $3.657M
YoY Change 141.59% 60.21%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $11.501 Million

About Apollomics Inc.

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company is headquartered in Foster City, California and currently employs 45 full-time employees. The company went IPO on 2021-11-26. The firm uses both targeted, immuno-oncology, and other approaches to address a range of cancer indications, such as acute myeloid leukemia, lung cancer, brain cancer, and other solid tumors. The product candidates in its pipeline are categorized into three groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumour inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Its advanced product candidate is vebreltinib (APL-101), a potent, oral active, highly selective c-Met inhibitor. Its anti-cancer enhancer product candidates include uproleselan (APL-106) and are antagonists of a cell adhesion receptor called E-selectin. Its immuno-oncology product candidates consist of APL-501, APL-502, APL-801 and APL-810. Its other product candidates include APL-122, APL-102, and APL-108.

Industry: Pharmaceutical Preparations Peers: Oruka Therapeutics, Inc. Tectonic Therapeutic, Inc. Orgenesis Inc. SOLENO THERAPEUTICS INC Eledon Pharmaceuticals, Inc. Vistagen Therapeutics, Inc. MAIA Biotechnology, Inc. Shuttle Pharmaceuticals Holdings, Inc. Tonix Pharmaceuticals Holding Corp.